BLCO (Bausch & Lomb) Short Interest


BLCO Bausch & Lomb Corp BLCO
77 GF Score
Price $15.91
GF Value $18.60
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bausch & Lomb Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

BLCO vs ISRG, BDX, MDLN: Short Interest Comparison

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb Short Interest vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's Short Interest distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's Short Interest falls into.


BLCO
77GF Score
Bausch & Lomb Corp BLCO
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bausch & Lomb (BLCO) Overvalued in 2026?

Based on GuruFocus' analysis, Bausch & Lomb stock appears to be undervalued. The current stock price of $15.91 is trading 14.5% below its estimated GF Value™ of $18.60. GuruFocus considers Bausch & Lomb to be Modestly Undervalued.

Key valuation signals for BLCO:

  • Short Interest:
  • GF Value™: $18.60 vs. price of $15.91 (14.5% below fair value)
  • GF Score™: 77/100 with 8 warning signs

No single metric tells the full story. See the BLCO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bausch & Lomb Business Description

Other Exchanges S2L:GermanyBLCO:Canada
Address 520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
77GF Score

Get the complete analysis for BLCO

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.91
Price
$18.60
GF Value